| HOME >> BIOLOGY >> TECHNOLOGY |
Major biopharmaceutical companies with substantial internal mammalian cell culture capability are forecast to have adequate internal manufacturing capacity. Contract mammalian cell culture manufacturers (CMOs) however, are likely to feel the pressure of increased utilization rates. For these CMOs and biopharmaceutical companies depending on them, understanding critical demand drivers, market factors and manufacturing trends is instrumental to making effective strategic supply decisions.
Fairfax, VA (PRWEB) December 2, 2008 -- Major biopharmaceutical companies with substantial internal mammalian cell culture capability are forecast to have adequate internal manufacturing capacity. Contract mammalian cell culture manufacturers (CMOs) however, are likely to feel the pressure of increased utilization rates. For these CMOs and biopharmaceutical companies depending on them, understanding critical demand drivers, market factors and manufacturing trends is instrumental to making effective strategic supply decisions.
"Cell Culture Manufacturing Capacity: Trends and Outlook through 2013" provides a timely and detailed examination of these issues. In this definitive report, foremost experts BioProcess Technology Consultants and PharmSource Information Services provide an extensive supply and demand analysis in addition to in-depth recommendations for the cell culture industry. Detailed data points include: product pipeline analysis, probable product success rates, time to market, API requirements, current and planned capacity, process yields and the potential impact of technology advances including biosimilars. "This report offers valuable strategic insight to support critical 'make or buy' decisions for mammalian cell culture manufacturers, key recommendations for capital investments and clear pricing strategy direction for the biologics contract manufacturing industry," comments Bi
'/>"/>
| Source: PRWeb Copyright©2008 Vocus, Inc. All rights reserved |